Development of comprehensive river typology based on macrophytes in the mountain-lowland gradient of different Central European ecoregions

The aim of the study was to identify the vegetation pattern in the different types of watercourses basing on survey in reference conditions in a wide geographical gradient, including mountain, upland and lowland rivers. We tested relationship between composition of macrophytes to environmental variables including: altitude, slope, catchment area, geology of valley, land use, hydromorphological sfeatures, water physical and chemical measurements. Analysis based on 109 pristine river sites located throughout major types of rivers in Central Europe. Qualitative and quantitative plant surveys were carried out between 2005 and 2013. Based on TWINSPAN classification and DCA analysis, six macrophyte types were distinguished. The lowland sites were divided into the following three types: humic rivers and two types of siliceous rivers depending on the catchment area, including medium-large and small rivers. The mountain and upland rivers were divided into three geological types: siliceous, calcareous and gravel. We found that the variation of macrophyte communities was determined by several habitat factors (mainly altitude, flow type, riverbed granulometry, conductivity and alkalinity), whereas the spatial factor was rather limited; further, the plant diversity was not reflected accurately by the European ecoregion approach

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

Metals in Racomitrium lanuginosum from Arctic (SW Spitsbergen, Svalbard archipelago) and alpine (Karkonosze, SW Poland) tundra

Item does not contain fulltex

Pleurozium schreberi as bioindicator of mercury pollution in heavily industrialized region

Contains fulltext : 123470.pdf (publisher's version ) (Open Access